Print Page     Close Window     

SEC Filings

SERES THERAPEUTICS, INC. filed this Form 8-K on 10/16/2017
Entire Document

Slide 3

PRECLINICAL PHASE 1b PHASE 2 Synthetically fermented Infectious Inflammatory SER-301 Inflammatory Bowel Disease (IBD) SER-262 Primary C. difficile Top line SER-287 Phase 1b data disclosed in October 2, 2017 press release; Collaboration with Nestlé Health Science regarding C. difficile and IBD programs for markets only outside of North America SER-155 Prevention of infection and GVHD following hematopoietic stem cell or solid organ transplant  Biologically sourced SER-287 Ulcerative colitis PHASE 3 SER-109 Recurrent C. difficile Research Collaborations CLINICAL PROGRAMS Positive top-line Phase 1b results Robust microbiome therapeutics pipeline

© Seres Therapeutics. All Rights Reserved.